Vascular Cell Adhesion Molecule-1 (VCAM-1/CD106): A Dual-Role Mediator in Cancer Pathogenesis and Inflammation – Supported by ANT BIO PTE. LTD.

1. Concept

Vascular Cell Adhesion Molecule-1 (VCAM-1/CD106) is a cytokine-inducible surface glycoprotein and member of the immunoglobulin superfamily. It features 6-7 extracellular Ig-like domains, a transmembrane domain, and a cytoplasmic domain, predominantly expressed on activated endothelial cells with additional expression on some hematopoietic and cancer cells. VCAM-1 mediates cell-cell interactions by binding to α4β1 and α4β7 integrins, playing pivotal roles in immune cell recruitment during inflammation and cancer progression. As a dual-purpose biomarker and therapeutic target, it is closely linked to inflammatory bowel disease (IBD) and colitis-associated colorectal cancer (CAC), with elevated expression correlating with disease severity, tumor stage, and metastasis.

2. Research Frontiers

Recent advances in VCAM-1 research have deepened our understanding of its dual roles in inflammation and cancer, with key frontiers focusing on therapeutic innovation, mechanism refinement, and clinical translation:

• Dual-Targeted Therapies: Development of agents targeting VCAM-1/α4 integrin interactions that simultaneously alleviate IBD and prevent CAC progression. This addresses the unmet need for chemopreventive strategies in high-risk IBD patients.
• Biomarker Precision: Optimization of soluble VCAM-1 as a non-invasive biomarker for monitoring IBD activity and predicting CRC risk. Combining VCAM-1 with other inflammatory markers improves diagnostic accuracy and prognostic stratification.
• Therapeutic Agent Diversification: Beyond approved antibodies (e.g., natalizumab) and small molecules (e.g., carotegrast methyl), novel strategies include anti-VCAM-1 antibodies, antisense oligonucleotides (ASOs), and targeted drug delivery systems—enhancing efficacy and reducing off-target effects.
• Mechanism Exploration: Uncovering VCAM-1’s role in tumor angiogenesis and immune microenvironment modulation. Research focuses on how VCAM-1-mediated leukocyte recruitment promotes cancer cell invasion and metastasis.
• Combination Therapy: Evaluating combinations of VCAM-1-targeted agents with immunotherapies (e.g., PD-1 inhibitors) or chemotherapy to synergistically inhibit CRC progression, leveraging VCAM-1’s role in immune cell infiltration.

3. Research Significance

VCAM-1 research holds profound significance for addressing the intertwined pathogenesis of IBD and CRC. As a key mediator of both intestinal inflammation and cancer metastasis, it offers a unique target to disrupt disease progression at multiple stages. For IBD patients at high risk of CAC, VCAM-1-targeted therapies provide a dual benefit: alleviating inflammation and reducing cancer risk.

From a biological perspective, studying VCAM-1’s integrin-binding mechanisms enhances our understanding of cell adhesion in inflammation and cancer. Its role in immune cell recruitment and tumor cell metastasis reveals how chronic inflammation drives carcinogenesis, providing insights into broader disease mechanisms.

Clinically, VCAM-1 advances diagnostics (non-invasive biomarker) and therapeutics (targeted agents) for colorectal diseases. Approved drugs like natalizumab and carotegrast methyl have already transformed treatment for IBD, while ongoing research expands their utility to CRC prevention.

Translational research on VCAM-1 drives the development of novel dual-purpose therapies, bridging inflammatory and cancer research. For the scientific community, VCAM-1 serves as a model for studying inflammation-cancer crosstalk, informing research on other adhesion molecules and their roles in disease.

4. Related Mechanisms, Research Methods, and Product Applications

Core Mechanisms

• Inflammatory Regulation: VCAM-1 is upregulated on endothelial cells during inflammation (e.g., IBD), binding α4β1/α4β7 integrins on immune cells to promote leukocyte recruitment and infiltration—exacerbating mucosal inflammation and immune dysregulation.
• Cancer Progression: VCAM-1 overexpression on CRC cells interacts with α4 integrin-expressing leukocytes/endothelial cells, facilitating cancer cell invasion, angiogenesis, and metastasis. Soluble VCAM-1 in serum correlates with tumor stage and poor prognosis.
• Therapeutic Targeting: Agents blocking VCAM-1/α4 integrin interactions (antibodies, small molecules, ASOs) inhibit leukocyte recruitment in IBD and cancer cell metastasis in CRC, exerting anti-inflammatory and anti-tumor effects.

Research Methods

• Expression Analysis: Techniques such as immunohistochemistry (IHC), flow cytometry, Western blotting, and ELISA detect VCAM-1 expression on cells and soluble VCAM-1 in serum/plasma.
• Functional Assays: In vitro adhesion assays (leukocyte-endothelial cell binding), Transwell invasion assays, and angiogenesis assays evaluate VCAM-1’s role in cell recruitment and cancer progression. In vivo AOM/DSS-induced CAC mouse models assess therapeutic efficacy of VCAM-1-targeted agents.
• Mechanism Studies: Co-immunoprecipitation and surface plasmon resonance (SPR) validate VCAM-1-integrin binding. Gene silencing (siRNA/shRNA) investigates VCAM-1’s impact on inflammation and metastasis.

Product Applications by ANT BIO PTE. LTD.

ANT BIO PTE. LTD. provides high-quality research tools to support VCAM-1-focused studies:

• STARTER Brand (Antibodies): Offers VCAM1 recombinant rabbit mAb (S0B0407) optimized for IHC, Western blotting, and flow cytometry—enabling precise detection of VCAM-1 in tissues and cells.
• UA Brand (Recombinant Proteins): Supplies Human VCAM-1/CD106 Protein (S0A1148, HEK293-expressed, His-tagged) for functional assays, integrin-binding studies, and antibody screening.
• Absin Brand (Kits & Reagents): Provides ELISA kits for quantifying soluble VCAM-1 and α4 integrin, as well as reagents for cell adhesion and invasion assays—streamlining experimental workflows.

5. Brand Mission

At ANT BIO PTE. LTD., our mission is to empower global life science researchers, gastroenterologists, and oncologists by delivering high-quality, reliable reagents that advance VCAM-1 research and translational medicine. We are committed to supporting inflammation and cancer research through our specialized sub-brands: STARTER (high-specificity antibodies), UA (high-purity recombinant proteins), and Absin (reliable kits & reagents). Leveraging advanced development platforms—including recombinant monoclonal antibody technology, multi-system protein expression (E.coli, CHO, HEK293, Insect Cells), and One-Step ELISA platforms—we adhere to rigorous quality standards (compliant with EU 98/79/EC, ISO9001, and ISO13485 certifications) to ensure product consistency and performance. Our dedication to innovation, quality, and customer-centricity drives us to contribute to advancements in colorectal disease diagnosis, treatment, and prevention.

6. Related Product List

7. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.